Related Experiment Video
Updated: Nov 19, 2025
04:15
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
2.1K
Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in
Junaid Ansari1,2, Elena Y Senchenkova1, Shantel A Vital1
1Department of Molecular and Cellular Physiology.
Blood
|January 29, 2021
Summary
Targeting the annexin A1 (AnxA1)/formyl peptide receptor (FPR2/ALX) pathway with AnxA1Ac2-26 peptide resolves thrombosis in sickle cell disease (SCD) models. This approach regulates neutrophils, offering potential new therapies for thromboinflammatory conditions.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Neutrophils are key players in thrombosis and inflammation.
- Altered neutrophil function contributes to thromboinflammatory diseases like sickle cell disease (SCD).
- Annexin A1 (AnxA1) promotes inflammation resolution through formyl peptide receptors (FPRs).
Purpose of the Study:
- To investigate the role of the AnxA1/FPR2/ALX pathway in SCD.
- To evaluate the therapeutic potential of AnxA1 mimetic peptide AnxA1Ac2-26 in SCD.
Main Methods:
- Administration of AnxA1Ac2-26 peptide to sickle transgenic mice.
- Analysis of neutrophil phenotype and activation markers.
- Assessment of cerebral thrombotic responses.
- Investigation of downstream signaling pathways including Akt and ERK1/2.
Main Results:
- AnxA1Ac2-26 peptide ameliorated cerebral thrombotic responses in SCD mice.
- The peptide regulated the FPR2/ALX pathway, crucial for resolution.
- Activated neutrophils in SCD were modulated by AnxA1Ac2-26 via Akt and ERK1/2 signaling.
- Direct evidence confirmed neutrophils' role in SCD thromboinflammation.
Conclusions:
- Targeting the AnxA1/FPR2/ALX pathway is a promising therapeutic strategy for SCD.
- AnxA1Ac2-26 peptide demonstrates potential for treating thromboinflammatory conditions.
- Modulation of neutrophil signaling pathways is key to achieving inflammation resolution in SCD.
